

Monday, 16 February 2026

Group CEO and Executive Director - Update

Australian Clinical Labs (**ACL**, the **Company**) wishes to announce that Group CEO and Executive Director Melinda McGrath has confirmed that she will not be renewing her contract following its conclusion on 30 August 2026.

Melinda has been an integral part of ACL's growth story over the last 10 years working tirelessly to grow the company organically, through acquisition and including its IPO on the ASX in 2021. The Board wishes to thank Melinda for her outstanding contribution and leadership of ACL and wishes her all the very best in her future endeavours.

Group CEO and Executive Director, Melinda McGrath, said:

"I would like to take this opportunity to thank our pathologists and scientists for their leadership, and the broader Clinical Labs team for their passionate commitment to the service of our patients and referring medical practitioners. In particular, I would like to recognise the Clinical Labs executive and broader leadership teams, whose drive and innovative approach to the development of the business has been outstanding. It has been a privilege to work with them over the past ten years. I wish them and the Board the best in the future as they continue to grow the business."

An extensive recruitment process for the CEO role is currently underway, and a further update will be announced to the market at the appropriate time.

- ENDS -

This announcement was authorised for release to ASX by the Board of ACL. For further information regarding this announcement, please contact:

Investor Relations

Matthew Cordingley
Chief Financial Officer
Email: matthew.cordingley@clinicallabs.com.au
Phone: +61 (0) 409 287 681

Governance

Eleanor Padman
Company Secretary
Email: epadman@padmanadvisory.com.au
Phone: +61 (0) 422 002 918